Archer-Daniels-Midland reports Q2 results on July 28 with the Street deeply divided on valuation and the stock trading well above where most analysts think it belongs.
The most striking tension in the setup is between a stock that has rallied 13% over the past month to $85.92 and a mean analyst price target of $75.30 — roughly 12% below current levels. Morgan Stanley, maintaining an Underweight, nudged its target to just $60 on July 20, reflecting a view that the recent run has left fundamentals behind. JP Morgan also holds an Underweight with a $74 target. On the other side, UBS raised its Buy target to $95 in mid-June, citing constructive commodity dynamics. That $60-to-$95 range captures the genuine disagreement: bears see a stock pricing in a recovery that hasn't yet materialized in margins, while bulls point to ADM's earnings momentum — EPS revisions rank in the 90th percentile on a 90-day basis, and forward EPS growth ranks in the top decile of the broader universe. The EV/EBITDA multiple has drifted down modestly over the past month even as the stock climbed, suggesting the earnings base is doing some of the work, but the PE has expanded by nearly 1.8 turns over 30 days — enough to raise the valuation question the bears are asking.
Short sellers are not pressing their case aggressively into this print. Short interest is running at 3.6% of the free float — not negligible, but unremarkable for a large-cap commodities processor. More telling is the direction: shorts trimmed positions by roughly 2.8% over the past week, and borrow conditions give them no urgency to cover. Availability in the lending market is extremely loose at roughly 1,670% — meaning there are about 17 shares available to borrow for every one currently lent out. Cost to borrow is just 0.54%, barely above last week's level. Nothing in the lending market signals a squeeze setup or forced covering. The ORTEX short score is stable at 40, well within neutral territory.
Options positioning adds little heat to the debate. The put/call ratio is 0.47, essentially in line with its 20-day average of 0.47, with a z-score just under 1. Neither side is loading up on directional bets. The PCR sits near its 52-week low end, suggesting the options market is not treating this as a high-risk event despite the stock's sharp monthly move.
One contextual note from recent history: after the last two earnings events, ADM shares rose roughly 2.3% on the day and held gains over the following five days. The upcoming print will test whether a stock trading above its consensus target — against a backdrop of strong earnings-estimate momentum but compressed agricultural margins — can justify the distance the rally has already traveled.
See the live data behind this article on ORTEX.
Open ADM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
